MedWatch

Companies fail one after the other: Why the Alzheimer’s mystery remains unsolved

One drug group after the other has burned its fingers in the attempt to develop treatments against Alzheimer’s Disease. Since year 2000, only one new therapy has entered the market. But why is Alzheimer’s such a tough nut to crack?

Photo: /ritzau/Asger Ladefoged

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try us for 14 days

Try a trial subscription for access to our quality journalism

Frontpage right now

Nævn afviser tilskud til Novos fedmemiddel

Prisen for fedmemidlet Saxenda fra Novo Nordisk står ikke mål med effekten, mener Lægemiddelstyrelsens Medicintilskudsnævn, der har indstillet til, at danske patienter ikke skal have tilskud til behandling med midlet uden en særlig god forklaring.

Related articles